<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Inosine pranobex (United States: Not available): Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Inosine pranobex (United States: Not available): Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Inosine pranobex (United States: Not available): Drug information</div><div class="clear"></div><div id="topicText"><div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
(For additional information <a class="drug drug_patient" data-topicid="88726" href="/d/html/88726.html" rel="external">see "Inosine pranobex (United States: Not available): Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="list canbnlist drugH1Div drugBrandNames" id="F52871568"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>Imunovir</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F16222941"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Antiviral Agent</li></ul></div>
<div class="block doa drugH1Div" id="F16222976"><span class="drugH1">Dosing: Adult</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="878dc45e-4adf-4d37-a3a4-0460082b1e74">Subacute sclerosing panencephalitis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Subacute sclerosing panencephalitis:</b>
<b>Oral:</b> 50 mg/kg/day in 3 to 4 equally divided doses (maximum: 3 g daily).</p></div>
</div>
</div>
<div class="block dora drugH1Div" id="F50990268"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There is no dosage adjustment provided in manufacturer’s labeling.</p></div>
<div class="block doha drugH1Div" id="F50987470"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There is no dosage adjustment provided in manufacturer’s labeling.</p></div>
<div class="block doe drugH1Div" id="F16222977"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">Refer to adult dosing.</p></div>
<div class="block dop drugH1Div" id="F16222975"><span class="drugH1">Dosing: Pediatric</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="878dc45e-4adf-4d37-a3a4-0460082b1e74">Subacute sclerosing panencephalitis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Subacute sclerosing panencephalitis (SSPE):</b> Refer to adult dosing.</p></div>
</div>
</div>
<div class="block dorp drugH1Div" id="F51159582"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There is no dosage adjustment provided in manufacturer’s labeling.</p></div>
<div class="block dohp drugH1Div" id="F51159583"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There is no dosage adjustment provided in manufacturer’s labeling.</p></div>
<div class="block adr drugH1Div" id="F16222949"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:-2em;margin-left:2em;">Frequency not defined:</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Pruritus, skin rash</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Hyperuricemia</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Constipation, diarrhea, gastric distress</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Hyperuricuria, increased urine output</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Dizziness, fatigue, headache, insomnia, nervousness</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Arthralgia</p></div>
<div class="block coi drugH1Div" id="F16222945"><span class="drugH1">Contraindications</span>
<p style="text-indent:0em;display:inline">There are no contraindications listed in the manufacturer’s product monograph.</p></div>
<div class="block war drugH1Div" id="F16222946"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Uric acid: Inosine undergoes rapid metabolism to uric acid. Use with caution in patients with a history of gout, urolithiasis, nephrolithiasis, or kidney impairment. Uricosuric agents (eg, probenecid) or antihyperuricemic therapy (eg, allopurinol) may be necessary for extremely elevated serum uric acid levels.</p></div>
<div class="block prod-avail drugH1Div" id="F16222985"><span class="drugH1">Product Availability</span>
<p style="text-indent:0em;display:inline">Not available in the US</p></div>
<div class="block geq drugH1Div" id="F53040759"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">No</p></div>
<div class="block dinfoc drugH1Div" id="F52871569"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Imunovir: 500 mg</p></div>
<div class="block adm drugH1Div" id="F16222980"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">
<b>Oral:</b> Administer orally in 3 to 4 equally divided doses while awake.</p></div>
<div class="block admp drugH1Div" id="F52622713"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">Oral: Administer orally in 3 to 4 equally divided doses while awake.</p></div>
<div class="block use drugH1Div" id="F16144139"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:0em;display:inline">
<b>Note:</b> Not approved in the US.</p>
<p style="text-indent:-2em;margin-left:2em;">Treatment of slowly progressive subacute sclerosing panencephalitis; may delay neurologic deterioration and prolong life expectancy.</p></div>
<div class="block cyt drugH1Div" id="F16265510"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F16265508"><span class="drugH1">Drug Interactions</span>
<br/><br/><div class="clear"></div><p style="text-indent:0em;display:inline">There are no known significant interactions.</p></div>
<div class="block pri drugH1Div" id="F16222944"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;display:inline">Adverse effects to the fetus were not observed in animal reproduction studies. Due to the altered immune status of patients who are pregnant, subacute sclerosing panencephalitis may be exacerbated during pregnancy and may progress rapidly. Because this condition is rare, use of inosine pranobex in pregnancy is limited to case reports (Cole 2007).</p></div>
<div class="block mop drugH1Div" id="F16222983"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Uric acid (serum and urine)</p></div>
<div class="block pha drugH1Div" id="F16222966"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Exact mechanism has not been fully elucidated; may possess antiviral and immunomodulating effects by potentiating T-lymphocyte and macrophage cell function and by influencing cytokine production (Milano, 1991; Petrova, 2010; Wybran, 1978). </p></div>
<div class="block phk drugH1Div" id="F16222968"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Rapid to uric acid; also undergoes glucuronidation and oxidation</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination: ~50 minutes (Campoli-Richards, 1986)</p>
<p style="text-indent:-2em;margin-left:2em;">Time to peak: 1 hour (Campoli-Richards, 1986)</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Urine (as uric acid, glucuronide and oxide metabolites, and unchanged drug)</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F22059524"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Immunovir | Isoprinosine</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Isoprinosine</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Ino protect | Isoprinosine | Izoreks | Viruprinol</span>;</li>
<li>
<span class="countryCode">(CL)</span> <span class="country">Chile</span><span class="countrySeparator">: </span><span class="drugName">Isoprinosine</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Deltax | Pranosina</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Isoprinosine | Modimunal</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Delimmun</span>;</li>
<li>
<span class="countryCode">(DO)</span> <span class="country">Dominican Republic</span><span class="countrySeparator">: </span><span class="drugName">Isoprinosine</span>;</li>
<li>
<span class="countryCode">(EC)</span> <span class="country">Ecuador</span><span class="countrySeparator">: </span><span class="drugName">Inmuflu | Isoprinosine | Virux</span>;</li>
<li>
<span class="countryCode">(EG)</span> <span class="country">Egypt</span><span class="countrySeparator">: </span><span class="drugName">Isoprinosine</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Bodaril</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Isoprinosine</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Imunovir | Imunovir nye</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Isoprinosine</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Imin | Isoprinosine</span>;</li>
<li>
<span class="countryCode">(HR)</span> <span class="country">Croatia</span><span class="countrySeparator">: </span><span class="drugName">Isoprinosine ewopharma</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Isoprinosine | Isoprivir</span>;</li>
<li>
<span class="countryCode">(ID)</span> <span class="country">Indonesia</span><span class="countrySeparator">: </span><span class="drugName">Beprin | Isoprinosine | Isprinol | Lanavir | Laprosin | Methisoprinol | Methopi | Moprin | Pronovir | Soprinol | Visoprine</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Imunovir | Isoprinosine</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Viralex</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Viruxan</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Isoprinosine</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Inoflic | Inoplix | Inopurix | Inosiplex | Prinosine | Serinosin</span>;</li>
<li>
<span class="countryCode">(KW)</span> <span class="country">Kuwait</span><span class="countrySeparator">: </span><span class="drugName">Isoprinosine</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Delimmun | Isoprinosine | Modimunal</span>;</li>
<li>
<span class="countryCode">(LU)</span> <span class="country">Luxembourg</span><span class="countrySeparator">: </span><span class="drugName">Isoprinosine</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Delimmun | Groprinosin | Isoprinosine | Modimunal</span>;</li>
<li>
<span class="countryCode">(MA)</span> <span class="country">Morocco</span><span class="countrySeparator">: </span><span class="drugName">Isoprinosine</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Isoprinosine | Pranosine</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Isoprinosine | Isoprinosine ewopharma</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Imunovir</span>;</li>
<li>
<span class="countryCode">(PE)</span> <span class="country">Peru</span><span class="countrySeparator">: </span><span class="drugName">Isoprinosine | Pranogir</span>;</li>
<li>
<span class="countryCode">(PH)</span> <span class="country">Philippines</span><span class="countrySeparator">: </span><span class="drugName">Immunosin | Inosiplex | Isoprinosine</span>;</li>
<li>
<span class="countryCode">(PK)</span> <span class="country">Pakistan</span><span class="countrySeparator">: </span><span class="drugName">Isoprinosine</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Eloprine | Groprinosin | Inuprin | Isoprinosine | Modimunal | Neosine | Neosine forte | Viruzine forte</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Isovir</span>;</li>
<li>
<span class="countryCode">(PY)</span> <span class="country">Paraguay</span><span class="countrySeparator">: </span><span class="drugName">Viruxan</span>;</li>
<li>
<span class="countryCode">(RO)</span> <span class="country">Romania</span><span class="countrySeparator">: </span><span class="drugName">Isoprinosine ewopharma</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Groprinosin | Isoprinosin | Isoprinosine | Normomed</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Imin | Isoprinosine</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Inomed | Isoprinosine</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">Isoprinosine</span>;</li>
<li>
<span class="countryCode">(TN)</span> <span class="country">Tunisia</span><span class="countrySeparator">: </span><span class="drugName">Isoprinosine</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Imin | Ishutin | Isolin | Isoprin | Isoprinosine | Methisine | Virux</span>;</li>
<li>
<span class="countryCode">(UA)</span> <span class="country">Ukraine</span><span class="countrySeparator">: </span><span class="drugName">Gropivirin | Groprim | Groprinosin | Inoseda | Isoprinosine | Normomed | Novirin | Novirin forte</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-2431857">
<a name="2431857"></a>Campoli-Richards, Sorkin EM, and Heel RC, “Inosine Pranobex. A Preliminary Review of Its Pharmacodynamic and Pharmacokinetic Properties, and Therapeutic Efficacy,” <i>Drugs</i>, 1986, 32(5):383-424.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/inosine-pranobex-united-states-not-available-drug-information/abstract-text/2431857/pubmed" id="2431857" target="_blank">2431857</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-4350802">
<a name="4350802"></a>Chang TW and Weinstein L, “Antiviral activity of Isoprinosine <i>in vitro</i> and <i>in vivo</i>,” <i>Am J Med Sci</i>, 1973, 265(2):143-6.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/inosine-pranobex-united-states-not-available-drug-information/abstract-text/4350802/pubmed" id="4350802" target="_blank">4350802</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17687135">
<a name="17687135"></a>Cole AJ, Henson JW, Roehrl MH, et al. Case records of the Massachusetts General Hospital. Case 24-2007. A 20-year-old pregnant woman with altered mental status. <i>N Engl J Med</i>. 2007;357(6):589-600.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/inosine-pranobex-united-states-not-available-drug-information/abstract-text/17687135/pubmed" id="17687135" target="_blank">17687135</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Imunovir.1">
<a name="Imunovir.1"></a>Imunovir (inosine pranobex) [product monograph]. Swords, Co Dublin, Ireland: KoRa Healthcare; October 2012.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1722191">
<a name="1722191"></a>Milano S, Dieli M, Millott S, et al, “Effect of Isoprinosine on IL-2, IFN-ϒ and IL-4 Production <i>in vivo</i> and <i>in vitro</i>,” <i>Int J Immunopharmacol</i>, 1991, 13(7):1013-8.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/inosine-pranobex-united-states-not-available-drug-information/abstract-text/1722191/pubmed" id="1722191" target="_blank">1722191</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6194125">
<a name="6194125"></a>Ohnishi H, Kosuzume H, Inaba H, et al, “The Immunomodulatory Action of Inosiplex in Relation to its Effects in Experimental Viral Infections,” <i>Int J Immunopharmacol</i>, 1983, 5(3):181-96.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/inosine-pranobex-united-states-not-available-drug-information/abstract-text/6194125/pubmed" id="6194125" target="_blank">6194125</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20038210">
<a name="20038210"></a>Petrova M, Jelev D, Ivanova A, et al, “Isoprinosine Affects Serum Cytokine Levels in Healthy Adults,” <i>J Interferon Cytokine Res</i>, 2010, 30(4):223-8.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/inosine-pranobex-united-states-not-available-drug-information/abstract-text/20038210/pubmed" id="20038210" target="_blank">20038210</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-80429">
<a name="80429"></a>Wybran J, Govaerts A, and Appelboom T, “Inosiplex, a Stimulating Agent for Normal Human T Cells and Human Leukocytes,” <i>J Immunol</i>, 1978, 121(3):1184-7.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/inosine-pranobex-united-states-not-available-drug-information/abstract-text/80429/pubmed" id="80429" target="_blank">80429</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 88326 Version 62.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
